Impact of a novel electronic monitor on psoriasis patient adherence to prescribed dose frequency and amount: Secondary analysis of a randomized trial

J Am Acad Dermatol. 2026 May 15:S0190-9622(26)02661-7. doi: 10.1016/j.jaad.2026.05.026. Online ahead of print.

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Electronic address: shafferb4567@gmail.com.
² Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
³ Sensal Health, Chapel Hill, North Carolina.
⁴ Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

No abstract available

Keywords: adherence; deucravacitinib; electronic monitor; oral medication; psoriasis.